Introduction
Asthma is a common chronic respiratory disease affecting more than 334 million individuals worldwide. It is characterized by airway inflammation, airway hyperresponsiveness, mucus hypersecretion, and airway remodeling. 1 Clinically, asthma presents with non-specific symptoms including wheezing, shortness of breath, chest tightness, and cough, making it a complex inflammatory airway disorder requiring long-term management strategies.
Pathophysiology and clinical burden
Asthma is primarily driven by chronic airway inflammation, which remains central to disease progression and symptom persistence. Airway hyperresponsiveness and mucus overproduction contribute to airflow limitation, while structural airway remodeling further exacerbates disease chronicity. In this context, controlling airway inflammation is a fundamental therapeutic target for improving disease outcomes. 2
Conventional management and limitations
The most commonly used pharmacological strategy for asthma includes daily administration of inhaled corticosteroids (ICS) combined with long-acting beta-agonists (LABA). While this approach is widely implemented, variability in symptom control is frequently observed across patients.3
Escalation of ICS dosage in cases of persistent symptoms or worsening disease may be associated with several adverse effects, including:
- Increased susceptibility to infections
- Gastrointestinal disturbances such as gastric ulcers and bleeding
- Metabolic effects including elevated blood glucose levels
- Electrolyte imbalance such as sodium retention and reduced serum potassium
- Cardiovascular effects such as hypertension
These limitations highlight the need for complementary therapeutic approaches targeting inflammatory pathways with improved safety profiles.
Bioactive profile of Piper longum and piperlongumine
Piper longum is a medicinal plant known for its bioactive compound piperlongumine, an amide derivative isolated from its roots. Piperlongumine exhibits multiple pharmacological properties, including:
- Analgesic activity
- Sedative effects
- Anti-inflammatory action
- Anxiolytic properties
- Antidepressant activity
- Antitumor potential
Its analogs also demonstrate significant anti-inflammatory effects by modulating inflammatory pathways, including inhibition of lipopolysaccharide-induced inflammation, suppression of collagen-induced arthritis, and regulation of neuroinflammatory responses.4
Mechanistic relevance in asthma
Piperlongumine is considered a potential candidate for asthma management due to its ability to regulate key inflammatory signaling pathways. Its activity is particularly associated with modulation of the NF-κB pathway, a central regulator of inflammatory gene expression involved in airway inflammation.
Key mechanistic actions include:
- Downregulation of NF-κB-mediated inflammatory signaling
- Reduction in inflammatory mediator activation
- Potential attenuation of airway inflammatory responses
Although promising, further evaluation is required to fully elucidate the molecular mechanisms involved in NF-κB regulation and to establish comprehensive preclinical pharmacodynamic profiles in asthma-related models. 5
Therapeutic relevance
Given its multi-target pharmacological profile, piperlongumine represents a potential adjunctive candidate in inflammatory airway disorders such as asthma. Its anti-inflammatory and immunomodulatory properties align with the primary therapeutic goal of asthma management, which is long-term control of airway inflammation and symptom reduction.
Conclusion
Asthma remains a chronic inflammatory airway disorder with significant global burden and therapeutic challenges. While conventional therapies provide symptom control, limitations in efficacy and safety necessitate exploration of complementary approaches. Piper longum-derived piperlongumine demonstrates promising anti-inflammatory and NF-κB-modulating potential, supporting its relevance as a candidate for further investigation in asthma management strategies.
References:
1. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783-800. doi:10.1016/S0140-6736(17)33311-1. https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(17)33311-1
2. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992;326(5):298-304. doi:10.1056/NEJM199201303260504. https://pubmed.ncbi.nlm.nih.gov/1530827/
3. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med. 2006;100(8):1307-1317. doi:10.1016/j.rmed.2005.11.020. https://linkinghub.elsevier.com/retrieve/pii/S0954-6111(05)00510-X
4. Bezerra DP, Pessoa C, de Moraes MO, Saker-Neto N, Silveira ER, Costa-Lotufo LV. Overview of the therapeutic potential of piplartine (piperlongumine). Eur J Pharm Sci. 2013;48(3):453-463. doi:10.1016/j.ejps.2012.12.003. https://www.sciencedirect.com/science/article/abs/pii/S0928098712004757?via%3Dihub